Streetbeat News

Revenues

HES

Hess Corporation (NYSE:HES) has been analyzed by 5 analysts in the last three months, showing a shift towards a more neutral stance with 4 indifferent ratings recently. The average 12-month price target for HES has been raised to $177.0, marking a 4.0% increase from the previous target of $170.20. Analysts from firms like Mizuho and Piper Sandler have adjusted their price targets, reflecting evolving market conditions and Hess's performance. Despite positive revenue growth, Hess faces challenges in net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:01 pm

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) has received mixed analyst ratings over the past three months, with a notable shift towards a more neutral stance in the last 30 days. Analysts have updated their price targets, reflecting an average target of $17.82, which is a 34.8% increase from the previous average of $13.22. This adjustment suggests a positive outlook on Fusion Pharmaceuticals' future market performance. The company, a clinical-stage biopharmaceutical firm focused on developing therapies for cancer, has shown significant revenue growth and a strong net margin, despite a below-average return on assets.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:01 pm

ITI

Four analysts have recently evaluated Iteris (NASDAQ:ITI), all maintaining a bullish stance with an updated average 12-month price target of $7.38, marking a 16.59% increase from the previous target of $6.33. Iteris, a provider of smart mobility infrastructure management solutions, has shown notable revenue growth and profitability, with a revenue growth rate of 3.55% as of December 31, 2023, and a net margin of 0.84%. The company's financial health is underscored by its low debt-to-equity ratio of 0.09 and strong returns on equity and assets.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:01 pm

RCM

R1 RCM (NASDAQ:RCM) received mixed analyst ratings over the past three months, with a total of 12 ratings. The ratings include 3 bullish, 6 somewhat bullish, and 3 indifferent. The average 12-month price target for RCM has increased to $15.92 from $14.67, indicating a positive sentiment shift. Analysts from firms like Canaccord Genuity, Citigroup, and RBC Capital have updated their ratings and price targets, reflecting various adjustments based on R1 RCM's performance and market conditions. R1 RCM, a provider of technology-driven solutions for healthcare providers, has shown a revenue growth rate of 7.84% and a net margin of 0.24%, outperforming industry benchmarks in financial health.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:00 pm

AVGO

Broadcom (NASDAQ:AVGO) has been analyzed by 31 analysts over the past three months, showing a positive shift in sentiment with an increase in the average 12-month price target to $1512.81 from $1315.00. The ratings range from bullish to indifferent, with a significant number of analysts raising their price targets. Broadcom's financials indicate a strong revenue growth rate of 34.17% as of January 31, 2024, but challenges in net margin, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 12:00 pm

MDXG

TELA

Tela Bio has sold the distribution rights for its NIVIS Fibrillar Collagen Pack to MiMedx, with an initial payment of $5M and future payments ranging from $3M-$7M based on NIVIS's net sales over the next two years.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 11:13 am

HLF

Herbalife projects Q1 sales growth of 1% to 3% and anticipates full-year 2024 sales growth to range between 0% and 5%.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 11:08 am

VEEV

Veeva Systems announced that its Vault EDC solution has surpassed the 1,000 study start milestone, with significant adoption among top biopharmaceutical companies and CROs. This marks a key achievement in the widespread use of modern electronic data capture (EDC) technologies in the industry.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 11:05 am

GIS

General Mills has reaffirmed its financial outlook for fiscal year 2024, projecting that its organic net sales will range from a 1% decrease to remaining flat. This announcement provides investors with a clear expectation of the company's performance in the near term.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 11:04 am

SIG

Signet Jewelers provided its financial outlook for FY25, projecting revenues of $6.66B to $7.02B, which is below the estimated $7.17B. The company also forecasts EPS to be between $9.08 and $10.48, compared to the estimated $10.57.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:56 am